PneumaCult™ 呼吸道类器官试剂盒

无血清和无BPE培养基用于呼吸道类器官的高效建立和分化

只有 %1 左

率先评论此产品

¥12,428.00

产品号 #（选择产品）

产品号 #05060_C

无血清和无BPE培养基用于呼吸道类器官的高效建立和分化

产品优势

生理相关。三维体外系统再现了体内人呼吸道。
优化。人呼吸道上皮细胞扩增和分化的完整系统，与PneumaCult™-Ex Plus兼容。
可靠。严格的原材料筛选和广泛的质控测试确保了高度的可重复性和最小的批次间差异性。
方便使用。不依赖于细胞培养小室，操作方便。

产品组分包括

PneumaCult™呼吸道类器官基础培养基，450 mL（产品号：#05061）；
PneumaCult™呼吸道类器官接种添加物，10ml（产品号：#05062）；
PneumaCult™呼吸道类器官分化添加物，40ml（产品号：#05063）

立即询价

总览

PneumaCult™气道类器官试剂盒是一种不含血清和BPE的培养体系，用于高效地建立和分化源自人支气管上皮细胞（HBECs）的呼吸道类器官。

在PneumaCult™-Ex Plus培养基（#05040）中进行2D扩增后，使用PneumaCult™呼吸道类器官接种培养基启动3D类器官培养，然后使用PneumaCult™呼吸道类器官分化培养基促进类器官形态发育，形成具有呼吸道生理特诊的结构。完全分化的人呼吸道器官再现了体内人呼吸道的关键特性，如被极化的呼吸道上皮细胞层包围的含有纤毛细胞和杯状细胞的空心腔。

呼吸道类器官的应用包括肺部疾病建模、药物筛选（疗效与毒性评估）以及呼吸道上皮功能研究。

浏览我们关于使用PneumaCult™培养呼吸道类器官的常见问题解答（FAQs）。

如果您打算将本产品用于商业目的，请通过www.huborganoids.nl与HUB联系，以获取商业用途许可或HUB许可相关的说明。

实验数据

Schematic of human airway organoid culture workflow using PneumaCult™ Airway Organoid Kit

Figure 1. Overview of the PneumaCult™ Culture System for Human Airway Organoid Generation

In the early two-dimensional expansion phase of the human airway organoid culture procedure, HBECs are expanded using PneumaCult™-Ex Plus Medium. The HBECs are then embedded into a Matrigel® dome and expanded for 4 - 7 days using PneumaCult™ Airway Organoid Seeding Medium. Following the expansion, the HBECs are differentiated using PneumaCult™ Airway Organoid Differentiation Medium for an additional 21+ days.

Fully differentiated human airway organoids generated using PneumaCult™ Airway Organoid Kit display physiologically relevant morphology.

Figure 2. Fully Differentiated Human Airway Organoids Generated Using PneumaCult™ Airway Organoid Kit

(A) Bright-field image of airway organoids growing in PneumaCult™ Airway Organoid Seeding Medium at day 7 exhibit basal cell spheroid morphology. (B) Bright-field image of airway organoids differentiated in PneumaCult™ Airway Organoid Differentiation Medium at day 21 exhibit hollow lumens. (C) Airway organoid stained for ZO-1 (junction protein marker, red), MUC5AC (goblet cell marker, purple), AC-Tubulin (ciliated cell marker, green), and DAPI (nuclei, blue).

Comparison of Forskolin-treated airway organoids derived from healthy donors and CF donors.

Figure 3. Forskolin-Induced Swelling of Airway Organoids

(A) Forskolin-treated organoids derived from healthy donors increased in size compared to the DMSO control, indicating functional CFTR protein expression. (B) Forskolin-induced swelling is lost in organoids derived from CF donors, but re-established in VX-809-treated airway organoids. Error bars represent ± 95% confidence interval for the mean (n=3). Bright-field images of airway organoids taken during the Forskolin swelling assay at (C) 0 hours and (D) 6 hours show organoid swelling after treatment.

Ciliated cell percentage in fully differentiated airway organoids derived from healthy and cystic fibrosis (CF) donors using PneumaCult™ Airway Organoid Kit at different passages.

Figure 4. Fully Differentiated Airway Organoids Retain Morphological Characteristics at Different Passages

The ciliated cell percentage in organoids grown from (A) healthy and (B) CF donors using PneumaCult™ Airway Organoid Kit increased from P3 to P5. The total and ciliated cells were counted using a hemocytometer. Error bars represent ± 95% confidence interval for the mean (n=3).

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

PneumaCult™ Airway Organoid Kit

Catalog #

05060

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

PneumaCult™ Airway Organoid Kit

Catalog #

05060

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

PneumaCult™ Airway Organoid Kit

Catalog #

05060

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

PneumaCult™ Airway Organoid Kit

Catalog #

05060

Lot #

All

Language

English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

文献 (2)

The CXCL8/MAPK/hnRNP-K axis enables susceptibility to infection by EV-D68, rhinovirus, and influenza virus in vitro Q. Yang et al. Nature Communications 2025 Feb

Abstract

Respiratory viruses pose an ongoing threat to human health with excessive cytokine secretion contributing to severe illness and mortality. However,the relationship between cytokine secretion and viral infection remains poorly understood. Here we elucidate the role of CXCL8 as an early response gene to EV-D68 infection. Silencing CXCL8 or its receptors,CXCR1/2,impedes EV-D68 replication in vitro. Upon recognition of CXCL8 by CXCR1/2,the MAPK pathway is activated,facilitating the translocation of nuclear hnRNP-K to the cytoplasm. This translocation increases the recognition of viral RNA by hnRNP-K in the cytoplasm,promoting the function of the 5′ untranslated region in the viral genome. Moreover,our investigations also reveal the importance of the CXCL8 signaling pathway in the replication of both influenza virus and rhinovirus. In summary,our findings hint that these viruses exploit the CXCL8/MAPK/hnRNP-K axis to enhance viral replication in respiratory cells in vitro. Subject terms: Virus-host interactions,Chemokines,Antimicrobial responses,Viral host response

View publication

CFTR Modulator Response in Nasal Organoids Derived from People with Cystic Fibrosis S. L. Cicero et al. Cells 2025 Dec

Abstract

Despite the progressive extension of CFTR variant eligibility to the triple combination of elexacaftor/tezacaftor/ivacaftor (ETI),most rare CFTR pathogenic variants remain ineligible for CFTR modulators. It is crucial to determine whether unexplored variants are rescuable by clinical modulators and to identify innovative therapeutic strategies for rescuing non-responder variants. The approach known as “theratyping” (in vitro testing of genotypes) has been accepted by the Food and Drug Administration (FDA) for the extension of clinical modulators’ approval for in vitro responding genotypes. We used one of the most advanced models for theratyping: organoids derived from nasal epithelia of people with cystic fibrosis (pwCF). We optimized the forskolin-induced swelling (FIS) of organoids to assess CFTR basal or modulator-restored function. Nasal organoids mimicked the original epithelial tissue,CFTR residual activity,and modulator response. We set up the FIS assay using nasal organoids with reference genotypes and theratyped 38 rare (non-F508del) CFTR genotypes,either eligible or non-eligible for FDA approval,for treatment with ETI or ivacaftor. We found strong correspondence between the in vitro response of CFTR variants to modulators and their FDA approval status. Additionally,some previously uncharacterized CFTR variants have proven responsive to clinical modulators,with significant therapeutic implications. These results suggest that the nasal organoid FIS assay,pending confirmation of the prediction in the corresponding pwCF,might be considered as a powerful in vitro tool to predict modulator efficacy in each pwCF,guiding out-of-label prescription in CF,and to identify uncharacterized variants responsive to modulators. This approach may allow comparison of the efficacy of different therapeutics or the identification of innovative strategies for non-responding genotypes,improving personalized therapy and quality of life for pwCF.

View publication

View All Publications

更多信息
物种	人
配方	无血清

更多信息

物种

人

配方

无血清

PneumaCult™ 呼吸道类器官试剂盒

产品号 #05060

产品号 #（选择产品）

产品号 #05060_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

PneumaCult™ 呼吸道类器官试剂盒

产品号 #05060

产品号 #（选择产品）

产品号 #05060_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

技术资料 (26)

文献 (2)

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台